Genelux (GNLX) Total Liabilities (2022 - 2026)

Genelux (GNLX) posted quarterly Total Liabilities of $9.5 million for Q1 2026, up 26.3% quarter-over-quarter from $7.5 million in Q4 2025.

Genelux (GNLX) Total Liabilities (2022 - 2026) Analysis & Trends

Genelux's Total Liabilities history runs 5 years deep, the most recent figure standing at $9.5 million for Q1 2026.

In Q1 2026, Total Liabilities changed N/A year-over-year to $9.5 million; the TTM figure through Mar 2026 stood at $9.5 million (changed N/A YoY), while the FY2025 annual figure was $7.5 million, down 11.36% from the prior year.
Total Liabilities for Q1 2026 stood at $9.5 million, up from $7.5 million in the prior quarter.
The five-year high for Total Liabilities was $41.3 million in Q4 2022, with the low at $6.4 million in Q3 2025.
The 5-year median for Total Liabilities is $8.4 million (2023), against an average of $11.3 million.
The sharpest annual moves came in 2023 and 2025: Total Liabilities plunged 79.62% in 2023, then climbed 11.17% in 2025.
Genelux's Total Liabilities stood at $41.3 million in 2022, then slumped by 79.62% to $8.4 million in 2023, then gained by 0.26% to $8.4 million in 2024, then retreated by 11.36% to $7.5 million in 2025, then advanced by 26.3% to $9.5 million in 2026.
Business Quant data shows GNLX's Total Liabilities at $9.5 million in Q1 2026, $7.5 million in Q4 2025, and $6.4 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Liabilities (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	7.18 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	10.02 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.62 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	4.20 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	4.00 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	4.20 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	1.35 Bn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	10.03 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	3.22 Bn
10	Genelux	120.53 Mn	120.53 Mn	-	9.45 Mn

Download Data